Earnings call transcripts

Management framed 2024 as a share-taking year, with targeted investment and pricing offsetting uneven end-market recovery and rising operating costs.

Management framed 2023 as the cyclical bottom, with improving markets supporting deployment, fundraising and eventual realizations despite prolonged real-estate caution.

The call framed 2024 as a bottoming cycle, with volume recovery and self-help offsetting weak construction, durable goods, and oversupply.

Management framed record enrollment as validation of durable demand, improving execution, and a broader opportunity across education and workforce markets.

Management framed 2024 as another strong investment year, with solid rail demand offsetting higher interest, maintenance, labor and lower remarketing income.

Management framed 2024 as a strong launch-and-procedure-recovery year, while acknowledging MedTech margin pressure and a milder XARELTO decline.

Management framed 2024 as a stabilization year, with deposit discipline, hedging, and back-half recovery offsetting muted demand and credit normalization.

Management framed 2024 as a volume-recovery year, with pricing and raw materials broadly neutral but restructuring and acquisitions driving profit growth.

Management framed 2024 around self-help, portfolio rationalization and a difficult San Ciprián funding decision.

Management framed 2024 as an optimization year, with improving domestic demand, international momentum and substantial but unquantified efficiency upside.

Management framed stabilization as underway, with Endpoint recovery and portfolio investments supporting second-half growth despite tougher Advanced Solutions comparisons.

Management framed the realignment as a shift toward higher-margin aftermarket cash flows, with new-build projects treated as upside rather than required for targets.